Investigation Launched into Option Care Health's Officers and Directors Following Major Stock Losses
In a significant development for investors in Option Care Health (NASDAQ: OPCH), an investigation has been initiated by Levi & Korsinsky, a well-known securities litigation firm. This inquiry comes on the heels of a troubling downward revision of FY 2026 revenue guidance by the company, leading to substantial financial losses for shareholders.
On February 24, 2026, during the fourth quarter earnings call, CFO Meenal Sethna reassured investors by reaffirming an optimistic revenue forecast of $5.8 billion to $6 billion, showcasing a projected growth rate of approximately 4% at the midpoint of the range. The management consistently expressed confidence in achieving these targets, which further instilled optimism among shareholders. However, just 65 days later, on April 30, the narrative changed dramatically when the company reported its first-quarter results, slashing its financial forecast to a range of $5.675 billion to $5.775 billion. This represented a significant reduction of up to 3.75% from the previously announced guidance.
As a direct consequence, OPCH shares witnessed an alarming plunge of approximately 26.4% at market open, reflecting the loss of confidence among investors. The announcement cited a rise in projected challenges, including a deteriorating retention rate of low-cost for chronic illness drugs and an unfavorable therapy mix for its patients, which negatively impacted its market standing and financial projections.
Levi & Korsinsky’s investigation focuses on determining whether the statements made by Option Care Health were materially false or misleading regarding its financial outlook, specifically concerning the FY 2026 revenue and adjusted EBITDA guidance reiterated just weeks before the stock plummet. The investigation supports investors who may have suffered from the unexpected financial strategies implemented by the company’s leadership.
Those who purchased shares of OPCH and experienced losses are encouraged to reach out to Levi & Korsinsky to explore their legal options. Joseph E. Levi, Esq., a partner at the firm, is leading the charge on this inquiry and can be contacted via email at [email protected] or by phone at (212) 363-7500.
The firm emphasizes that eligibility for participation in the investigation is based on documented losses suffered between specific purchase dates, regardless of whether the investors still hold their shares. Given the gravity of the situation, many investors are likely eager to understand their rights and options moving forward.
Along with engaging in this investigation, the law firm reassures prospective participants that the entire process operates on a contingency basis. Thus, individuals would incur no upfront costs or fees, making it a risk-free opportunity for those seeking to recover their losses.
Furthermore, joining this investigation does not necessitate any court appearances or depositions, facilitating a worry-free pathway for shareholders looking to seek redress.
In a broader context, this incident reflects the ongoing volatility faced by companies in the health sector and underscores the importance of transparency and accuracy in financial reporting. Investors are urged to remain vigilant and informed, especially when companies exhibit uncertain performance metrics.
Historically, Levi & Korsinsky has established itself as a formidable player in securities litigation, having successfully recovered hundreds of millions for aggrieved shareholders across various cases. The firm's reputation is built on its rigorous approach to ensuring accountability among corporate executives and their financial practices.
As this investigation unfolds, it will be crucial for stakeholders to stay updated on any new developments which might influence their holdings and the overall market perception of Option Care Health. This case serves as an essential reminder of the responsibilities that come with corporate governance and the importance of sound investment strategies for all parties involved.
On February 24, 2026, during the fourth quarter earnings call, CFO Meenal Sethna reassured investors by reaffirming an optimistic revenue forecast of $5.8 billion to $6 billion, showcasing a projected growth rate of approximately 4% at the midpoint of the range. The management consistently expressed confidence in achieving these targets, which further instilled optimism among shareholders. However, just 65 days later, on April 30, the narrative changed dramatically when the company reported its first-quarter results, slashing its financial forecast to a range of $5.675 billion to $5.775 billion. This represented a significant reduction of up to 3.75% from the previously announced guidance.
As a direct consequence, OPCH shares witnessed an alarming plunge of approximately 26.4% at market open, reflecting the loss of confidence among investors. The announcement cited a rise in projected challenges, including a deteriorating retention rate of low-cost for chronic illness drugs and an unfavorable therapy mix for its patients, which negatively impacted its market standing and financial projections.
Levi & Korsinsky’s investigation focuses on determining whether the statements made by Option Care Health were materially false or misleading regarding its financial outlook, specifically concerning the FY 2026 revenue and adjusted EBITDA guidance reiterated just weeks before the stock plummet. The investigation supports investors who may have suffered from the unexpected financial strategies implemented by the company’s leadership.
Those who purchased shares of OPCH and experienced losses are encouraged to reach out to Levi & Korsinsky to explore their legal options. Joseph E. Levi, Esq., a partner at the firm, is leading the charge on this inquiry and can be contacted via email at [email protected] or by phone at (212) 363-7500.
The firm emphasizes that eligibility for participation in the investigation is based on documented losses suffered between specific purchase dates, regardless of whether the investors still hold their shares. Given the gravity of the situation, many investors are likely eager to understand their rights and options moving forward.
Along with engaging in this investigation, the law firm reassures prospective participants that the entire process operates on a contingency basis. Thus, individuals would incur no upfront costs or fees, making it a risk-free opportunity for those seeking to recover their losses.
Furthermore, joining this investigation does not necessitate any court appearances or depositions, facilitating a worry-free pathway for shareholders looking to seek redress.
In a broader context, this incident reflects the ongoing volatility faced by companies in the health sector and underscores the importance of transparency and accuracy in financial reporting. Investors are urged to remain vigilant and informed, especially when companies exhibit uncertain performance metrics.
Historically, Levi & Korsinsky has established itself as a formidable player in securities litigation, having successfully recovered hundreds of millions for aggrieved shareholders across various cases. The firm's reputation is built on its rigorous approach to ensuring accountability among corporate executives and their financial practices.
As this investigation unfolds, it will be crucial for stakeholders to stay updated on any new developments which might influence their holdings and the overall market perception of Option Care Health. This case serves as an essential reminder of the responsibilities that come with corporate governance and the importance of sound investment strategies for all parties involved.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.